345 results about "Angiopathy" patented technology

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and / or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and / or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

The novel amidino derivatives of the formula (I):wherein all the symbols are as in specification defined;have an inhibitory activity of a blood coagulation factor VIIa and are useful for treatment and / or prevention of several angiopathy caused by enhancing a coagulation activity, such as disseminated intravascular coagulation, coronary thrombosis, cerebral infarction, cerebral embolism, transient ischemic attack, cerebrovascular disorders, pulmonary vascular diseases, deep venous thrombosis, peripheral arterial obstruction, thrombosis after artificial vascular transplantation and artificial valve transplantation, post-operative thrombosis, reobstruction and restenosis after coronary artery bypass operation, reobstruction and restenosis after PTCA or PTCR, thrombosis by extracorporeal circulation and procoagulative diseases such as glomerlonephriitis.

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and / or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

A method for reconstructing 3D blood vessels belongs to the field of medical detection technology for solving the accuracy problem in blood vessel reconstruction. The technical scheme is that the method can accurately reconstruct the anatomic structure of a blood vessel by combining cross section information of the blood vessel acquired by an IVUS image sequence and ultrasonic duct spatial geometrical information obtained by 3D reconstruction based on X-ray angiographic images. Compared with the reconstruction result obtained by using two single images, the method can completely and accurately reflect the actual shapes of blood vessels and possibly-existing plaques, thus providing more reliable basis for clinical treatment of coronary heart diseases and other angiopathies.

The present invention provides novel benzene compounds presented by the following formulas, and analogs thereof, that exert an ACC activity-inhibiting effect that is effective in the treatment of obesity, hyperlipemia, fatty liver, hyperglycemia, impaired glucose tolerance, diabetes, diabetic complications (diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, and diabetic macroangiopathy, hypertension, arteriosclerosis), hypertension, and arteriosclerosis.

Provided are methods for treating inflammatory neurodegenerative diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke / cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline; mild cognitive impairment and prion diseases in a mammal), or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and / or modulating the function and / or activity of effector T-cells, and / or for cell-based tolerogenic therapy (e.g., by modulating development and / or function and / or activity of TREG cells and / or dendritic cells (DCs) and / or TH17 cells (e.g., RORγt+ TH17 cells). In certain aspects such methods comprise ex vivo exposure of T-cells and / or APC (e.g., dendridic cells) to at least one electrokinetically-altered fluid as disclosed herein. Combination therapies are additionally provided.

The invention discloses a non-invasive central aortic blood pressure measuring method and device. The non-invasive central aortic blood pressure measuring method includes, according to a human artery network model based on viscous fluid mechanics, a method of calculating artery network model personalized parameters of a measured person through measured radial artery and brachial artery pulse wave signals and arm blood pressure values, a method of calculating an ascending aorta-radial artery transfer function and a method of calculating central arterial pressure waveforms through measured central arterial pressures. The non-invasive central aortic blood pressure continuous measuring device comprises a pulse wave signal processing and analysis unit and a radial artery and brachial artery pulse wave signal acquisition unit worn on a wrist. The method is different from an existing general transfer function method, the artery network model parameters of each person to be measured are measured and calculated and the artery network model parameters are numerical characteristics of the cardiovascular system states of the person to be measured with the calculated central arterial pressure waveforms, and the method and device has important meanings in prevention, curing and control of cardiovascular diseases, especially high-risk diseases, such as hypertensions and coronary heart diseases.

The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and / or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and / or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and / or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma. The formula I-II is shown in the description.

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and / or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

The invention relates to a preparation method and application of an electrochemical immunosensor for a biomarker, namely a recombinant proprotein convertase subtilisin kexin type 9 (pcsk9) protein for predicting and diagnosing cardiovascular diseases, and belongs to the technical field of electrochemical detection. The preparation method is characterized by comprising the following steps: firstly, performing nitrogen doping on a graphene nanobelt (n-gnrs), performing amination on a fullerene-palladium-platinum nanoparticle (n-C60 / pdpt) composite material and a staphylococcus aureus a protein (spa), and performing layer-by-layer self-assembling so as to immobilize a pcsk9 antibody (ab1); mixing the synthesized nanoparticle-poly-methylene blue (pt-pmb) with the pcsk9 antibody (ab2), and preparing a nano beacon, thereby obtaining the electrochemical immunosensor for pcsk9 protein detection. The electrochemical immunosensor has the advantages of being high in sensitivity, good in specificity and rapid and convenient in detection. A novel method for pcsk9 protein detection is provided, and useful information is provided for clinical prediction and diagnosis on cardiovascular diseases.

The present invention is directed to the compound of formula I which is useful for inhibiting the activity of blood clotting enzyme Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically treating a patient suffering from, or subject to, a disease state associated with a cardiovascular disorder.

The present invention relates to the compounds of the formula (I) and salts thereof (all the symbols are the same meanings as described in the specification).The compounds of the formula (I) possess inhibitory activity of N-type calcium channel, so they are useful as drug for prevention and / or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis, epilepsy, asthma and pollakiuria etc. or agent for the treatment of pain.

An apparatus for diagnosing an angiopathy of a living subject, including a first pulse-wave-propagation-velocity-related-information obtaining device which obtains a first pulse-wave-propagation-velocity-related information that is related to a first velocity at which a first pulse wave propagates through a first interval of the subject, a second pulse-wave-propagation-velocity-related-information obtaining device which obtains, at a substantially same time as a time when the first pulse-wave-propagation-velocity-related-information obtaining device obtains the first pulse-wave-propagation-velocity-related information, a second pulse-wave-propagation-velocity-related information that is related to a second velocity at which a second pulse wave propagates through a second interval of the subject that is different from the first interval, and a comparison-value calculating device for calculating a comparison value based on the first pulse-wave-propagation-velocity-related information and the second pulse-wave-propagation-velocity-related information.

A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I):wherein Z is C═O or a covalent bond; Y is H or O(C1–C4)alkyl, R1 and R2 are individually (C1–C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H or together with R3 is —CH2—CH2— or —S—, R5 is I, O(C1–C4)alkyl or H, and R6 is I, O(C1–C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and / or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (I).

The invention relates to a method and device for measuring the autonomic nerve heart regulation and control function. The wearable device, an autonomic nerve heart regulation and control function mathematical model and an autonomic nerve heart regulation and control system parameter calculation method are involved in the method. The wearable device is used for measuring motion data, continuous blood pressure and a heart rate value sequence in a human body standing-up or inclining test. The autonomic nerve heart regulation and control function mathematical model is used for quantitatively describing the blood pressure and heart rate regulation and control process in the standing-up process. According to the autonomic nerve heart regulation and control system parameter calculation method, a series of autonomic nerve heart regulation and control system parameters such as pressure sensor sensitivity and sympathetic nerve and parasympathetic nerve activity are solved based on the autonomic nerve heart regulation and control function mathematical model and the continuous blood pressure and the heart rate value sequence measured in the standing-up or inclining test through the wearable device. Autonomic nerve regulation and control disorders are represented by reduction of the pressure sensor sensitivity and reduction of the sympathetic nerve and parasympathetic nerve activity, which are the occurrence origins and independent indexes of many lethal cardiovascular diseases. Quantitative measurement of the pressure sensor sensitivity and the sympathetic nerve and parasympathetic nerve activity is of great significance on effective diagnosis and prevention of cardiovascular diseases, evaluation of treatment effects and recovery of patients.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and / or CDR-grafted anti-Gas6 antibodies. The invention also provides for the nucleic acids encoding such peptides and anti-Gas6 antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, including therapeutic formulations, administration and devices. Fifteen novel peptide sequences from the Gas6 G domain that are implicated in Gas6 interactions with its receptors are identified, isolated, and synthesized so as to allow generation of anti-Gas6 antibodies. The peptide sequences include three ESTs that encompass regions predicted to contribute to receptor binding or that can raise anti-Gas6 antibodies. This invention provides for such antibodies to be used in modulating or treating at least one Gas6-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, thromboembolic disease, ischemic disease, venous thromboembolism, arterial or venous thrombosis, pulmonary embolism, restenosis, diabetic angiopathy and allograft atherosclerosis.

The present invention relates to a medical health data collection based intelligent health forecasting and decision-making system. The system is characterized by comprising the following steps: 1) data collection; 2) transmission of data to a cloud server, wherein a cloud ICVD paroxysm evaluation module processes the data; 3) doctor platform information processing; and 4) patient platform information processing. The cloud part of the scheme comprises a 10-year ischemic cardiovascular disease (abbreviated as ICVD) probability forecasting and doctor decision-making system. According to the scheme of the present invention, a cloud technology platform can assist doctors to collect health data of a patient, establish health records, and forecast a 10-year ICVD probability, so that a personalized health program is created for the patient, and the treatment decision-making system is established.

The invention discloses heart-protection and blood-nourishing flour and a preparation method thereof. The heart-protection and blood-nourishing flour is prepared from 60-70 parts by weight of wheat, 30-40 parts by weight of wheat germ, 25-30 parts by weight of black soya bean, 20-25 parts by weight of Chinese yam, 21-25 parts by weight of water chestnut, 22-26 parts by weight of banana, 20-30 parts by weight of carrot, 10-14 parts by weight of gingko seed, 16-20 parts by weight of dried bean curd, 20-25 parts by weight of shepherd's purse, 18-20 parts by weight of green plum, 8-10 parts by weight of sweet osmanthus, 1-2 parts by weight of tree peony bark, 2-3 parts by weight of rhizoma alismatis, 3-4 parts by weight of lotus leaf, 2-3 parts by weight of stigma croci, 5-6 parts by weight of ginkgo leaf, 1-2 parts by weight of a food modifier and a proper amount of water. The heart-protection and blood-nourishing flour utilizes wheat, wheat germ and black soya bean as main raw materials. Wheat germ has effects of softening blood vessels, preventing and treating cardiovascular and cerebtovascular diseases, adjusting blood pressure, controlling blood sugar, protecting heart, improving human immunity, moistening intestines and relaxing bowel, delaying aging and expelling toxins. Chinese yam, water chestnut, banana and carrot having good health care performances are used in the heart-protection and blood-nourishing flour. Water chestnut has effects of strengthening spleen and tonifying qi, strengthening thigh and knee, improving physical power and tonifying qi, resisting cancers, reducing fat, inducing diuresis, promoting lactation and relieving or neutralizing the effect of alcohol. Ginkgo leaf has effects of promoting blood circulation, preventing cardiovascular diseases, promoting blood circulation to remove blood stasis, and whitening skin and removing wrinkles.

The invention discloses a CA-(PLA-ran-PCL)-b-PEG star amphiphilic copolymer, and a preparation method and an application thereof. The star copolymer adopts the structure as shown in the formula I, wherein R' refers to the specification. The method comprises the following steps: 1, preparing CA-(PLA-ran-PCL); 2, carboxylation of PEG; and 3, preparing the CA-(PLA-ran-PCL)-b-PEG star copolymer. The copolymer provided by the invention has favourable biocompatibility and biological degradability, and can be applied to the field of pharmaceutical preparations and tissue engineering, particularly the field of antitumor drugs preparations or anti-cardiovascular disease drugs preparations.

The invention discloses edible blend oil and its preparation method. The edible blend oil is prepared from, by weight, 20-30 parts of corn oil, 20-30g of soybean oil, 10-20 parts of rice oil, 10-20 parts of flaxseed oil, 5-10 parts of peanut oil, 1-2 parts of Vitamin E, 0.5-1 part of hydrolysis plant protein, and 0.5-1 part of green tea extractive. The raw material further comprises lycopene, citric acid and medlar extractive. The edible blend oil is high in nutrition value and good in oxidization stability; after eating for a long time, the edible blend oil has good effect to people with hyperlipidemia, high blood pressure and hyperglycemia, patients with cardia-cerebrovascular disease, fatty liver and obesity.